Severe hemophilia B

Severe hemophilia B, also known as severe Christmas disease or severe factor IX (FIX) deficiency, is a rare X-linked bleeding disorder caused by mutations in the F9 gene located on the X chromosome. In severe hemophilia B, factor IX clotting activity is less than 1% of normal levels, leading to a significantly impaired coagulation cascade. The condition primarily affects males, while females typically serve as carriers, though symptomatic carriers have been reported. The disease affects the hematologic system and can have secondary consequences on the musculoskeletal system due to recurrent bleeding. Patients with severe hemophilia B experience spontaneous bleeding episodes, particularly into joints (hemarthroses) and muscles, without any identifiable trauma. Commonly affected joints include the knees, ankles, and elbows. Repeated joint bleeds can lead to chronic hemophilic arthropathy, characterized by progressive joint destruction, pain, and disability. Other serious manifestations include intracranial hemorrhage, gastrointestinal bleeding, prolonged bleeding after surgery or dental procedures, easy bruising, and hematuria. Bleeding episodes often begin in infancy or early childhood, frequently when the child starts crawling or walking. The treatment landscape for severe hemophilia B has evolved significantly. Standard treatment includes prophylactic replacement therapy with plasma-derived or recombinant factor IX concentrates to prevent spontaneous bleeding. Extended half-life recombinant FIX products have reduced the frequency of infusions needed. Gene therapy has emerged as a transformative treatment option, with etranacogene dezaparvovec (Hemgenix) receiving regulatory approval as the first gene therapy for hemophilia B, offering the potential for sustained FIX expression and reduced or eliminated need for factor replacement. Emicizumab, a bispecific antibody approved for hemophilia A, is not effective in hemophilia B. Management of inhibitory antibodies (anti-FIX antibodies), which develop in approximately 1-5% of severe hemophilia B patients, remains a clinical challenge and may require immune tolerance induction or bypassing agents.

Common questions about Severe hemophilia B